FDA tees up a snap re­view for Dupix­ent as Sanofi, Re­gen­eron hunt 4th ap­proval for megablock­buster

With com­peti­tor af­ter com­peti­tor go­ing af­ter Dupix­ent for in­di­ca­tions such as atopic der­mati­tis, is it fi­nal­ly the drug’s turn to con­cede and drop? Well, if …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER